Anebulo Pharmaceuticals stock soars after approving plan to go private

Published 23/07/2025, 13:44
© Reuters.

Investing.com -- Anebulo Pharmaceuticals (NASDAQ:ANEB) stock surged 80% after the clinical-stage pharmaceutical company announced its Board of Directors approved a plan to go private through a reverse stock split that would terminate its registration as an SEC reporting company.

The company plans to implement a reverse stock split at a ratio between 1-for-2,500 and 1-for-7,500, with the exact ratio to be determined by the Board. Following the split, stockholders holding fewer shares than the minimum threshold will receive $3.50 per pre-split share in cash, representing a 91% premium over the July 22, 2025 closing price.

Anebulo, which develops solutions for acute cannabis-induced toxic effects, cited the "burdensome" costs of maintaining public company status as the primary reason for the decision. The company stated that going private aligns with its strategy to develop product candidates, reduce operating costs, and "return the maximum value to its stockholders."

The transaction, recommended by a Special Committee of independent directors, is subject to stockholder approval and other conditions. Stockholders who own more than the minimum threshold (between 2,500 and 7,500 shares) will continue to hold one post-split share for every minimum number of pre-split shares owned, plus cash for any fractional shares.

The Board retains the right to abandon the proposed transaction if it determines the move is no longer in the best interests of the company or its stockholders.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.